Twist Bioscience Strikes Lilly TuneLab Antibody Data Deal

M&A · PartnershipProduct / Tech
โดย Simply Wall St·US·Read original
Summary · why it matters

Twist Bioscience announced on 16 September 2026 an agreement with Lilly TuneLab under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly's AI/ML drug discovery models. The collaboration plugs Twist's DNA and antibody capabilities into Lilly's AI-driven discovery ecosystem, potentially deepening its role in data-rich, AI-enhanced antibody development workflows across the biopharma industry. The deal follows Twist's US$300,000,000 follow-on equity raise in August 2026, a pairing that highlights a company still funding growth externally while positioning itself as a preferred data and DNA supplier to big pharma and AI drug discovery partners. Twist's narrative projects $753.3 million in revenue and $127.9 million in earnings by 2029, yielding a $105.30 fair value, a 26% downside to its current price, while some of the most optimistic analysts already expected revenue of about US$715,300,000 and earnings of roughly US$128,500,000 by 2029. The agreement may reinforce that bullish view on AI-driven demand, though it does not by itself resolve the near-term issue of achieving a credible path toward breakeven or reduce dependence on a concentrated set of large NGS customers.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
Twist Bioscience Corp
TWST
▲ PositiveDemandrelevance

Twist wins an agreement to supply antibody characterization data services to Lilly's TuneLab, deepening its role as a preferred data/DNA supplier to big pharma.

Eli Lilly and Company
LLY
▲ PositiveTechnologyrelevance

Lilly's AI/ML drug discovery models gain high-quality antibody characterization data from Twist under the TuneLab agreement.

Theme Impact 2

Related news

ChemoMetec Posts Record DKK511 Million Revenue, Guides FY26/27 to DKK545-575 Million

ChemoMetec reported record revenue of DKK511 million for its Q4 2026 fiscal year, up 3% year over year and 7% at constant exchange rates, with EBITDA rising 9% to DKK281 million and the EBITDA margin expanding to 55% from 52.1%. Instrument revenue grew 13% on the strength of XM products including NC-203, whose revenue jumped to DKK68.1 million from DKK27.7 million a year earlier, while the life science business, representing 95% of group revenue, grew 6% to approximately DKK485 million. Consumables revenue fell 4% on the US federal government shutdown in fall 2025, US and Canada revenue slipped 6% in reported terms, and the animal semen, beer and milk business dropped 32% amid a continued market exit. The company repurchased 105,000 shares at year-end for about DKK39 million and roughly 206,600 shares, or 1.2% of share capital, as of the call date, and ended with a cash position of approximately DKK290 million and equity of approximately DKK725 million. For FY2026/27, ChemoMetec guided revenue to DKK545 million to DKK575 million, implying roughly 7% to 13% growth, EBITDA to DKK300 million to DKK330 million, and CapEx to approximately DKK120 million, with CEO Martin Behrens saying the outlook excludes any contribution from the Roche, Tecan and Hamilton collaborations and from delayed XM orders.
0DZ0.LSE
Biotech & Genomic Medicine
GuruFocus·13hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·1dRead more →
▲2

IP Group H1 2026 NAV Tops GBP1 Billion as Cash Proceeds Reach GBP69 Million

IP Group PLC reported that its net asset value exceeded GBP1 billion at the end of H1 2026, with NAV per share rising about 3% to 114p and reaching roughly 117p as of 11 September 2026. The company generated GBP69 million in cash proceeds during the half, up from GBP30 million a year earlier, plus GBP17 million after the period, bringing year-to-date proceeds to about GBP86 million and total proceeds since 2025 to GBP154 million, more than halfway toward its GBP250 million target by the end of 2027. Gross cash stood at GBP239 million at period end, while the portfolio was valued at roughly GBP900 million, or about 103p per share, with the top five assets accounting for about 50p per share. The Pfizer royalty interest rose GBP27 million to just over GBP150 million, and Oxford Nanopore posted GBP117 million in revenue, about 12% growth at constant currency, with gross margin up 400 basis points to 62% and its adjusted EBITDA loss more than halved to just over GBP22 million. Profit for the period was GBP31 million, effectively converted into cash, and about GBP50 million of proceeds is available for shareholder returns under the capital allocation policy.
2891.TWIPO.LSEONT.LSEPFE
Biotech & Genomic Medicine ▲
GuruFocus·1dRead more →
© 2026 MarketDXNews